Aldurazyme (laronidase) for a UAE family: what the pathway looks like in 2026
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-20.
A UAE family of a child with mucopolysaccharidosis type I, MPS I, walks into this decision with more than a treatment question. There is a clinical question about which form of MPS I the child carries and what that means for the therapy plan. There is a regulatory question about how Aldurazyme moves into the country. There is a financial question that is multi-decade, not multi-month. And there is a family question, often a heavy one, because in many MENA families MPS I has appeared in a relative before this child. This page is meant to be the first honest read you get on Aldurazyme in the UAE, written by the team that would coordinate around your child's case if you decided you wanted operational support on the workup, the import, the qualified infusion centre, or the long-term cost picture.
We will be specific about what MPS I is, what the workup decides, what the difference between severe Hurler and attenuated Scheie means for the treatment plan, what the regulatory pathway looks like in the UAE in 2026, how the written quote works, where the infusion can be given in the UAE, and what life looks like for a family settling into weekly lifelong infusions.
Ask about Aldurazyme in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
What MPS I actually is, in plain terms
Mucopolysaccharidosis type I, MPS I, is a lysosomal storage disorder. The IDUA gene normally produces an enzyme called alpha-L-iduronidase, which lives inside the lysosomes (the cellular recycling compartment) and breaks down two long-chain sugars called dermatan sulfate and heparan sulfate. When IDUA is faulty, those sugars accumulate, slowly, in every tissue. The accumulation is what causes the disease.
MPS I presents on a spectrum. Severe Hurler syndrome, the most-severe form, presents in infancy with coarse facial features, an enlarged liver and spleen, recurrent ear and chest infections, progressive heart valve disease, skeletal changes called dysostosis multiplex, and, critically, progressive cognitive decline. Hurler-Scheie syndrome, the intermediate form, presents later with the somatic features but normal or near-normal cognition. Scheie syndrome, the attenuated form, can be diagnosed in adolescence or adulthood, often with corneal clouding, joint stiffness, and milder somatic involvement.
The form your child has matters because Aldurazyme does not cross the blood-brain barrier. The enzyme reaches the heart, the lungs, the liver, the spleen, and the skeletal-somatic tissues, but it does not meaningfully address the cognitive decline of severe Hurler. For severe Hurler infants, the standard of care globally is hematopoietic stem cell transplantation, HSCT, ideally before age 2 to 2.5 years, because donor bone marrow cells produce enzyme that does cross into the CNS through engrafted microglia. Aldurazyme is used as a bridge to HSCT (controlling somatic disease during the months between diagnosis and transplant) and often as an adjunct afterwards. For Hurler-Scheie and Scheie patients, ERT alone is typically the long-term answer.
We mention this first because it is the most important piece of information for your family. Your metabolic specialist will tell you which form of MPS I your child has based on the IDUA mutation profile and the early clinical picture. The treatment plan that follows is built on that classification.
The workup that decides eligibility and shapes the plan
Many UAE families arrive at Reserve Meds at different diagnostic stages. Some have a complete MPS I workup already on file from Tawam Hospital in Al Ain, from SKMC, or from a paediatric metabolic service abroad. Others have been managed for individual organ manifestations for years, an enlarged liver here, recurrent ear infections there, joint stiffness, and the unifying MPS I diagnosis has not yet been confirmed. Both starting points are workable.
The diagnostic and pre-treatment workup has five components.
First, urinary glycosaminoglycan screen. Elevated urinary dermatan sulfate and heparan sulfate is the accessible first screen.
Second, alpha-L-iduronidase enzyme activity assay in leukocytes or fibroblasts. This is the definitive enzymatic confirmation. Deficient or absent activity diagnoses MPS I.
Third, IDUA gene sequencing. Identifies the specific pathogenic variants and helps with severity classification, family carrier testing, and prognostic conversations.
Fourth, baseline organ assessments. Echocardiogram for cardiac valve disease, pulmonary function testing including FVC, sleep study for apnea, ophthalmology for corneal clouding, ENT for upper airway and hearing, hepatomegaly assessment, joint range-of-motion documentation, baseline 6-minute walk test. These become the surveillance schedule for the rest of your child's life on therapy.
Fifth, severity classification by the metabolic specialist. Severe Hurler, Hurler-Scheie, or Scheie. The HSCT-versus-ERT-alone decision flows from this classification.
A clinical rationale letter from your metabolic specialist documents the diagnosis, the severity classification, the recommended treatment plan, and the long-term monitoring schedule.
The UAE regulatory pathway: how it actually works in 2026
The Emirates Drug Establishment, which absorbed 44 of the Ministry of Health and Prevention's regulatory functions by early 2026, is now the federal authority that the treating hospital files through. Aldurazyme has a long track record in MENA and; where formal registration is in place, standard prescription and import procurement applies, and where not, the named-patient mechanism is filed via ede.gov.ae by the hospital's import pharmacy on the treating physician's behalf. The Department of Health Abu Dhabi or Dubai Health Authority adds the emirate-level layer depending on where the infusion is given.
We give you a written timeline estimate for your case before you commit. Aldurazyme is treated as a benchmark rare-disease ERT and the regulatory framework is workable for it.
The realistic UAE infrastructure for MPS I: - Tawam Hospital, Al Ain. Tawam has a longstanding paediatric metabolic service that has managed UAE MPS patients for years. Strong infrastructure for the diagnostic workup, the weekly infusion schedule, and the multidisciplinary surveillance. - Sheikh Khalifa Medical City, Abu Dhabi. Paediatric metabolic and rare-disease infrastructure. Anaphylaxis-management capability for the infusion suite. - Burjeel Medical City, Abu Dhabi. Metabolic clinic. - American Hospital Dubai. Paediatric service capable of weekly ERT delivery for Dubai-side families. - Mediclinic City Hospital, Dubai. Paediatric subspecialty depth.
For severe Hurler patients, the HSCT pathway adds another layer. Cleveland Clinic Abu Dhabi and the BMT programmes operating in the UAE in 2026 handle paediatric BMT; some families travel to KFSHRC Riyadh or to international BMT centres for the transplant itself, with the ERT bridge managed in the UAE. Reserve Meds can coordinate either pattern.
The cost conversation, in the form a UAE family needs
Aldurazyme is given weekly for life, so the lifetime cost is what matters most.
Medicine price: quote on request. You get a written quote for your case before you commit. A 10 kg toddler runs at the low end; a 70 kg adolescent Scheie patient runs at the upper end. Medicine price: quote on request. You get a written quote for your case before you commit.
When we issue a quote at intake, we separate every line: drug per infusion, infusion-suite charges, pre-medication, monitoring labs (urinary GAG, anti-laronidase antibody titre, organ surveillance), our coordination fee. Nothing is bundled. We charge a transparent coordination fee for the case-management work, disclosed in writing before any funds move.
Insurance coverage of Aldurazyme in the UAE is uneven. Coverage depends on the plan and usually needs prior authorisation; insurers vary widely. We supply your insurer with the documentation packet. We do not process the claim or guarantee coverage.
For Emirati nationals being treated at SKMC or Tawam under the public system, much of the cost may be underwritten through the government health funding pathways. Your treating consultant will confirm whether and how. For expatriate residents, the cost picture is typically a mix of insurance coverage, employer support where applicable, and family-pay.
The weekly infusion reality
Aldurazyme is a weekly intravenous infusion of approximately 3 to 4 hours including the slow titration period. Pre-medication with an antihistamine (with or without an antipyretic) is given about 60 minutes before each infusion. For long-term patients, a central venous access device is often placed to make the weekly access manageable.
Infusion-associated reactions are common, particularly during the first months of therapy. The infusion suite must have anaphylaxis-management capability on site, with epinephrine, oxygen, IV access, trained nursing, and physician availability. Over time the reaction frequency typically decreases, but it does not go to zero.
For a UAE family, the practical implication is that weekly clinic time is a permanent feature of the calendar. School schedules, work schedules, extended-family visits, summer travel, and Ramadan are all planned around the infusion schedule. The infusion centre becomes a known place, and the nursing team becomes part of the family network. This is something many MPS families say openly once they have settled into it.
Monitoring on therapy
The surveillance schedule on long-term Aldurazyme is built around the multisystemic nature of MPS I: - Urinary GAG every 3 to 6 months (the primary biochemical efficacy marker). - Anti-laronidase antibody titre at intervals; some patients develop antibodies and the clinical implications are variable. - 6-minute walk test annually (functional efficacy). - FVC annually (pulmonary). - Echocardiogram annually (cardiac valve surveillance). - ECG annually. - Ophthalmology annually (corneal clouding). - ENT and audiology annually. - Sleep study as clinically indicated. - Orthopaedic and physiotherapy reviews on a schedule set by the team. - Hepatosplenomegaly assessment.
For Dubai-side families, American Hospital Dubai and Mediclinic City coordinate the multidisciplinary visits within the city.
When Aldurazyme is not the right answer, or not the only answer
For severe Hurler infants, ERT alone does not address the cognitive trajectory. The conversation your family will have with the metabolic specialist will include HSCT timing, donor matching, the BMT centre choice, and the role of Aldurazyme as bridge therapy before transplant and adjunct therapy after. We will not pretend this is a small decision. We can coordinate the BMT centre referral alongside the ERT pathway.
For severe Hurler patients who are diagnosed late, after the cognitive window for HSCT benefit has closed, the honest conversation is about palliating somatic progression with ERT while accepting that the CNS trajectory is on a different track. Your metabolic specialist will frame this candidly. Reserve Meds will support whatever the family and the treating team decide.
For patients with attenuated Scheie syndrome diagnosed in adulthood, the management picture is often closer to chronic-disease management of a multisystemic condition, with the cardiac, ophthalmic, and orthopaedic interventions sometimes mattering more day-to-day than the weekly ERT itself.
For families pursuing emerging therapies, the AAV-based gene therapy programmes for MPS I are in clinical trials internationally but are not yet approved. We can talk through trial eligibility and access where it applies, but we will not present trial therapy as routinely available.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
What Reserve Meds does, and what we do not do
Reserve Meds is a US-based digital health company that coordinates access to cross-border and complex specialty medicine. For a UAE family pursuing Aldurazyme, our scope is the regulatory documentation packet, the EDE filing in collaboration with your treating hospital's import pharmacy, the sourcing logistics from the manufacturer's authorised distribution through DSCSA-compliant chain of custody, cold-chain shipment to the qualified UAE centre (2-8 degrees Celsius, do not freeze), and named case-lead coordination from intake through the establishment of a stable weekly infusion routine. We continue to coordinate refills, documentation, and any cross-border travel for second opinions or for HSCT centre evaluation where it applies.
Reserve Meds is not your child's prescriber. We do not practise medicine. We do not manufacture Aldurazyme. We do not own or operate the infusion centre. We are not your insurer. Clinical decisions stay with your metabolic specialist and the infusion centre team; we are the operational layer that turns those decisions into a coordinated case.
We work cash-pay (where applicable). Our coordination fee is disclosed in writing. We will not start work without a signed engagement.
A note for families weighing this
Families who have religious questions about a medicine can discuss them with their own scholar or physician.
For families who already have an affected child or relative, the carrier-testing conversation for siblings and for the extended family is a separate but important thread, and your metabolic specialist will offer the appropriate referrals.
What to do if you want to start
The first concrete step is a call with our case-lead so we can confirm the diagnostic stage your child is at, the severity classification if it has been made, and whether the right next move is the workup, the ERT initiation, the HSCT pathway evaluation, or a combination.
If your child has been diagnosed with MPS I but you have not yet made the severity classification decision, reach out anyway: we will help you get the workup completed in-emirate before the treatment-plan conversation.
Most families reach us first on WhatsApp, which is the medium we hold open during UAE business hours and on weekends for active cases.
Start your child's case on the portal, or open a WhatsApp conversation with the case-lead and we will take it from there.
Illustrative example cases (composites, not real patients). This content is for general information and does not constitute medical advice. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating metabolic specialist and the infusion centre team.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-20.
Regulatory status of Aldurazyme (laronidase) in UAE, 2026
Aldurazyme (laronidase) is approved by the US Food and Drug Administration for the labelled indication of enzyme replacement therapy for mucopolysaccharidosis I (MPS I) (see the FDA approval record at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu). For a UAE-based patient, the access pathway runs through the Ministry of Health and Prevention (MOHAP) and Department of Health Abu Dhabi (DoH) framework. The official regulator portal is at www.mohap.gov.ae; the locally registered medicines list is at www.mohap.gov.ae/en/services/drug-registration.
Where Aldurazyme (laronidase) is held on the locally registered list at the time the case opens, standard prescription and in-country dispensing applies and the treating consultant at the prescribing tertiary centre coordinates supply through the institutional pharmacy. Where Aldurazyme (laronidase) is not yet on the locally registered list at the time the case opens, the named-patient and personal-import framework that the Ministry of Health and Prevention (MOHAP) and Department of Health Abu Dhabi (DoH) maintains for reference-authority-approved medicines is the operative route. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies), no locally available alternative is clinically equivalent for the specific patient indication, the treating physician of record takes documented clinical responsibility, and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility. Confirm current registration status at intake; the published registration list governs.
Tertiary centers and clinical coordination in UAE
The UAE tertiary referral network for a Aldurazyme (laronidase) case is concentrated at Cleveland Clinic Abu Dhabi (CCAD), Tawam Hospital Al Ain, Mediclinic Parkview Hospital Dubai, and Burjeel Medical City. These centers carry the haematology, oncology, neurology, metabolic, infectious-disease, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For enzyme replacement therapy (ERT) therapies that require specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For oral, subcutaneous, or in-clinic infusion therapies that can be administered in UAE once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Medicines are supplied through a US-licensed pharmaceutical wholesale partner under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, and Reserve Meds coordinates international shipment to the named dispensing facility and re-supply aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway runs through patient travel to a US-certified treatment center rather than import into UAE; the UAE tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.
UAE quotes and payer posture, 2026
Reserve Meds issues a written, itemised custom quote once the treating physician's documentation is in. Medicine price: quote on request. You get a written quote for your case before you commit.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds coordination, and any patient and caregiver travel and accommodation are itemised separately. For a complex case the total course cost includes treatment-centre fees, pre-treatment workup, on-treatment monitoring, complication management, and family logistics, as well as the medicine.
Payer posture in UAE is overwhelmingly cash-pay for named-patient imports and cross-border specialty cases. The relevant public-payer body is Daman (Abu Dhabi) and Dubai Health Authority (DHA Sehati and Dhamani); the portal is at www.doh.gov.ae. Public coverage generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Aldurazyme (laronidase) case in UAE are: (1) Regulatory documentation complexity. The Ministry of Health and Prevention (MOHAP) and Department of Health Abu Dhabi (DoH) named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with US-licensed pharmaceutical wholesale partners to secure Aldurazyme (laronidase) from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating UAE physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Aldurazyme (laronidase): the labelled indication is enzyme replacement therapy for mucopolysaccharidosis I (MPS I). The enzyme replacement therapy (ERT) mechanism shapes both the eligibility workup and the monitoring schedule. The relevant clinical-practice guideline body is MPS I International Consensus Panel and the European MPS Network at www.ncbi.nlm.nih.gov/pmc/articles/PMC2754327/. The treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Aldurazyme (laronidase) in UAE, 2026
The Ministry of Health and Prevention (MOHAP) and Department of Health Abu Dhabi (DoH) portal at www.mohap.gov.ae and the locally registered medicines list at www.mohap.gov.ae/en/services/drug-registration are the authoritative source for the current UAE listing status of Aldurazyme (laronidase); the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active Aldurazyme (laronidase) safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication for Aldurazyme (laronidase) remains enzyme replacement therapy for mucopolysaccharidosis I (MPS I) (see the current FDA approval record at accessdata.fda.gov). Sanofi (originating partnership with BioMarin) continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The MPS I International Consensus Panel and the European MPS Network guidance at www.ncbi.nlm.nih.gov/pmc/articles/PMC2754327/ remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.